Ushbu ishga iqtibos qilgan ishlar

5 ta ish

Ish: CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance

   Omer Qutaiba B. Allela, Abdulkareem Shareef, S. Renuka Jyothi +9

   MaqolaCAR-T cell therapy researchDiscover Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.001466

3. Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   MaqolaCAR-T cell therapy researchDiscover Oncology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.005310

4. Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers

   Ghaleb Oriquat, Waleed K. Abdulsahib, Sajida Hussein Ismael +6

   MaqolaImmune Cell Function and InteractionAnnals of Hematology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.005653

5. Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   MaqolaCancer Immunotherapy and BiomarkersAnnals of Hematology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.009488